Marian Rewers
Concepts (933)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 396 | 2026 | 3937 | 20.580 |
Why?
| | Autoimmunity | 139 | 2026 | 933 | 12.400 |
Why?
| | Islets of Langerhans | 126 | 2026 | 847 | 12.020 |
Why?
| | Autoantibodies | 192 | 2026 | 1509 | 11.450 |
Why?
| | Celiac Disease | 55 | 2026 | 311 | 7.200 |
Why?
| | Genetic Predisposition to Disease | 97 | 2026 | 2399 | 4.320 |
Why?
| | Coronary Artery Disease | 34 | 2018 | 750 | 3.210 |
Why?
| | Child, Preschool | 215 | 2026 | 11868 | 3.020 |
Why?
| | Diabetic Angiopathies | 28 | 2017 | 267 | 3.010 |
Why?
| | HLA-DQ Antigens | 38 | 2025 | 174 | 2.910 |
Why?
| | Child | 247 | 2026 | 22739 | 2.840 |
Why?
| | Calcinosis | 23 | 2015 | 234 | 2.740 |
Why?
| | HLA-DR Antigens | 28 | 2021 | 220 | 2.620 |
Why?
| | Insulin Resistance | 55 | 2018 | 1244 | 2.500 |
Why?
| | Insulin | 76 | 2026 | 2516 | 2.440 |
Why?
| | Infant | 172 | 2026 | 10090 | 2.400 |
Why?
| | Disease Progression | 83 | 2026 | 2865 | 2.370 |
Why?
| | Risk Factors | 167 | 2026 | 10917 | 2.240 |
Why?
| | Humans | 518 | 2026 | 145763 | 2.120 |
Why?
| | Diabetic Ketoacidosis | 16 | 2026 | 210 | 2.090 |
Why?
| | Polymorphism, Single Nucleotide | 40 | 2026 | 2181 | 2.030 |
Why?
| | Transglutaminases | 30 | 2026 | 159 | 2.000 |
Why?
| | Genotype | 64 | 2026 | 1857 | 1.980 |
Why?
| | Blood Glucose | 38 | 2022 | 2344 | 1.970 |
Why?
| | Autoimmune Diseases | 17 | 2026 | 469 | 1.940 |
Why?
| | Male | 353 | 2026 | 73003 | 1.910 |
Why?
| | Prospective Studies | 101 | 2026 | 8075 | 1.850 |
Why?
| | Female | 361 | 2026 | 79035 | 1.850 |
Why?
| | Biomarkers | 50 | 2026 | 4302 | 1.840 |
Why?
| | Adolescent | 150 | 2026 | 22573 | 1.830 |
Why?
| | Insulin Antibodies | 24 | 2026 | 103 | 1.820 |
Why?
| | Mass Screening | 24 | 2026 | 1361 | 1.790 |
Why?
| | Glutamate Decarboxylase | 35 | 2025 | 165 | 1.610 |
Why?
| | Hyperglycemia | 11 | 2026 | 379 | 1.570 |
Why?
| | Diabetic Nephropathies | 19 | 2020 | 322 | 1.540 |
Why?
| | Diet | 32 | 2026 | 1278 | 1.510 |
Why?
| | Insulin-Secreting Cells | 15 | 2023 | 392 | 1.450 |
Why?
| | Coronary Disease | 15 | 2010 | 382 | 1.410 |
Why?
| | HLA Antigens | 25 | 2026 | 240 | 1.390 |
Why?
| | Prediabetic State | 14 | 2023 | 250 | 1.380 |
Why?
| | Case-Control Studies | 60 | 2026 | 3634 | 1.360 |
Why?
| | Follow-Up Studies | 66 | 2026 | 5428 | 1.250 |
Why?
| | Health Care Costs | 2 | 2025 | 425 | 1.180 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 10 | 2022 | 48 | 1.170 |
Why?
| | Glutens | 11 | 2023 | 59 | 1.140 |
Why?
| | Cohort Studies | 69 | 2026 | 6032 | 1.130 |
Why?
| | Diabetes Mellitus, Type 2 | 36 | 2025 | 2602 | 1.100 |
Why?
| | Fatty Acids, Omega-3 | 8 | 2020 | 143 | 1.070 |
Why?
| | Enterovirus Infections | 6 | 2023 | 173 | 1.040 |
Why?
| | Polymorphism, Genetic | 15 | 2019 | 615 | 1.020 |
Why?
| | HLA-DR3 Antigen | 17 | 2025 | 76 | 1.010 |
Why?
| | Adult | 160 | 2026 | 40872 | 1.000 |
Why?
| | Environment | 5 | 2018 | 293 | 0.990 |
Why?
| | DNA Methylation | 8 | 2026 | 690 | 0.970 |
Why?
| | Infant, Newborn | 67 | 2026 | 6464 | 0.970 |
Why?
| | H(+)-K(+)-Exchanging ATPase | 2 | 2017 | 8 | 0.940 |
Why?
| | Erythrocyte Membrane | 5 | 2015 | 55 | 0.920 |
Why?
| | Longitudinal Studies | 32 | 2026 | 2967 | 0.900 |
Why?
| | Atherosclerosis | 15 | 2018 | 409 | 0.880 |
Why?
| | Colorado | 45 | 2026 | 4556 | 0.880 |
Why?
| | HLA-DR4 Antigen | 17 | 2025 | 74 | 0.880 |
Why?
| | Age of Onset | 20 | 2026 | 557 | 0.840 |
Why?
| | Incidence | 37 | 2026 | 2933 | 0.840 |
Why?
| | Middle Aged | 137 | 2025 | 36302 | 0.830 |
Why?
| | Diabetes Complications | 7 | 2019 | 225 | 0.810 |
Why?
| | Coronary Vessels | 8 | 2017 | 246 | 0.810 |
Why?
| | Albuminuria | 12 | 2016 | 189 | 0.810 |
Why?
| | Enterovirus | 5 | 2019 | 83 | 0.800 |
Why?
| | Seroconversion | 7 | 2026 | 48 | 0.780 |
Why?
| | Vitamin D | 8 | 2026 | 404 | 0.770 |
Why?
| | Proportional Hazards Models | 26 | 2024 | 1330 | 0.760 |
Why?
| | Vascular Calcification | 9 | 2018 | 110 | 0.760 |
Why?
| | Predictive Value of Tests | 25 | 2019 | 2123 | 0.720 |
Why?
| | Young Adult | 53 | 2026 | 14251 | 0.700 |
Why?
| | Glucose Tolerance Test | 26 | 2022 | 361 | 0.690 |
Why?
| | C-Peptide | 7 | 2025 | 190 | 0.670 |
Why?
| | Breast Feeding | 18 | 2021 | 447 | 0.660 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 12 | 2025 | 54 | 0.660 |
Why?
| | Inflammation | 10 | 2026 | 2883 | 0.650 |
Why?
| | Genetic Testing | 8 | 2019 | 483 | 0.650 |
Why?
| | Haplotypes | 15 | 2026 | 500 | 0.650 |
Why?
| | Fatty Acids | 6 | 2021 | 457 | 0.640 |
Why?
| | Calcium | 8 | 2023 | 1191 | 0.630 |
Why?
| | Zinc Transporter 8 | 8 | 2025 | 70 | 0.620 |
Why?
| | Blood Glucose Self-Monitoring | 6 | 2022 | 701 | 0.620 |
Why?
| | Antibodies, Viral | 6 | 2023 | 674 | 0.610 |
Why?
| | Autoantigens | 9 | 2025 | 427 | 0.600 |
Why?
| | GTP-Binding Proteins | 8 | 2026 | 153 | 0.590 |
Why?
| | Ascorbic Acid | 5 | 2026 | 184 | 0.560 |
Why?
| | Early Diagnosis | 7 | 2025 | 251 | 0.550 |
Why?
| | Prevalence | 23 | 2024 | 2874 | 0.550 |
Why?
| | Uric Acid | 6 | 2018 | 167 | 0.550 |
Why?
| | Infant Nutritional Physiological Phenomena | 5 | 2021 | 159 | 0.550 |
Why?
| | Cross-Sectional Studies | 36 | 2025 | 5922 | 0.530 |
Why?
| | Body Mass Index | 23 | 2025 | 2447 | 0.530 |
Why?
| | Germany | 12 | 2024 | 138 | 0.520 |
Why?
| | Logistic Models | 24 | 2017 | 2139 | 0.510 |
Why?
| | Smoking | 9 | 2025 | 1477 | 0.510 |
Why?
| | Infant Food | 7 | 2018 | 69 | 0.510 |
Why?
| | Adiponectin | 5 | 2016 | 242 | 0.500 |
Why?
| | Fatty Acids, Unsaturated | 2 | 2016 | 96 | 0.500 |
Why?
| | Sensitivity and Specificity | 22 | 2026 | 2000 | 0.500 |
Why?
| | Edible Grain | 4 | 2008 | 47 | 0.490 |
Why?
| | Finland | 16 | 2025 | 78 | 0.490 |
Why?
| | Prognosis | 21 | 2026 | 4329 | 0.490 |
Why?
| | Fibrinogen | 5 | 2019 | 180 | 0.490 |
Why?
| | Monitoring, Physiologic | 2 | 2009 | 289 | 0.480 |
Why?
| | Glomerular Filtration Rate | 15 | 2020 | 765 | 0.480 |
Why?
| | Metabolomics | 5 | 2021 | 733 | 0.480 |
Why?
| | Age Factors | 38 | 2026 | 3346 | 0.480 |
Why?
| | Arteriosclerosis | 17 | 2004 | 83 | 0.480 |
Why?
| | Adaptor Proteins, Signal Transducing | 3 | 2013 | 426 | 0.470 |
Why?
| | Thyroiditis, Autoimmune | 2 | 2026 | 16 | 0.460 |
Why?
| | Genome-Wide Association Study | 10 | 2026 | 1430 | 0.460 |
Why?
| | Hypoglycemia | 5 | 2014 | 480 | 0.450 |
Why?
| | Lipids | 5 | 2019 | 707 | 0.450 |
Why?
| | Triglycerides | 13 | 2020 | 520 | 0.450 |
Why?
| | Hypertension | 11 | 2021 | 1276 | 0.450 |
Why?
| | Milk | 7 | 2017 | 119 | 0.440 |
Why?
| | Prenatal Exposure Delayed Effects | 7 | 2025 | 655 | 0.440 |
Why?
| | Luminescent Measurements | 4 | 2021 | 75 | 0.440 |
Why?
| | Environmental Exposure | 4 | 2025 | 578 | 0.440 |
Why?
| | Probiotics | 3 | 2022 | 61 | 0.430 |
Why?
| | C-Reactive Protein | 5 | 2018 | 423 | 0.430 |
Why?
| | Helicobacter Infections | 1 | 2014 | 30 | 0.420 |
Why?
| | Helicobacter pylori | 1 | 2014 | 44 | 0.420 |
Why?
| | Risk | 17 | 2020 | 923 | 0.410 |
Why?
| | Respiratory Tract Infections | 5 | 2025 | 396 | 0.410 |
Why?
| | Antibodies | 5 | 2024 | 397 | 0.400 |
Why?
| | Micronutrients | 3 | 2026 | 102 | 0.400 |
Why?
| | Time Factors | 21 | 2018 | 7133 | 0.400 |
Why?
| | Asymptomatic Diseases | 3 | 2023 | 104 | 0.400 |
Why?
| | Dietary Supplements | 7 | 2024 | 584 | 0.400 |
Why?
| | Inflammation Mediators | 3 | 2026 | 507 | 0.400 |
Why?
| | Fatty Acids, Monounsaturated | 2 | 2014 | 55 | 0.400 |
Why?
| | Fatty Acid Desaturases | 1 | 2013 | 31 | 0.390 |
Why?
| | Sweden | 13 | 2024 | 115 | 0.390 |
Why?
| | Immunogenetics | 1 | 2013 | 8 | 0.390 |
Why?
| | Dyslipidemias | 4 | 2015 | 184 | 0.390 |
Why?
| | Alleles | 14 | 2021 | 896 | 0.380 |
Why?
| | Glucose Clamp Technique | 8 | 2020 | 199 | 0.380 |
Why?
| | Proteomics | 6 | 2025 | 1188 | 0.380 |
Why?
| | Risk Assessment | 17 | 2021 | 3752 | 0.370 |
Why?
| | HLA-D Antigens | 5 | 2019 | 30 | 0.370 |
Why?
| | Bacteriophages | 2 | 2025 | 110 | 0.370 |
Why?
| | United States | 35 | 2025 | 16123 | 0.370 |
Why?
| | Dietary Fats | 3 | 2014 | 308 | 0.370 |
Why?
| | Child Nutritional Physiological Phenomena | 4 | 2019 | 106 | 0.360 |
Why?
| | Oxylipins | 3 | 2023 | 47 | 0.360 |
Why?
| | Fasting | 12 | 2015 | 279 | 0.360 |
Why?
| | Cost-Benefit Analysis | 4 | 2026 | 644 | 0.360 |
Why?
| | Genetic Variation | 4 | 2026 | 976 | 0.360 |
Why?
| | Epitopes | 6 | 2025 | 473 | 0.350 |
Why?
| | Vitamin D Deficiency | 2 | 2011 | 190 | 0.350 |
Why?
| | Apolipoproteins A | 2 | 2006 | 19 | 0.350 |
Why?
| | Lipoproteins | 4 | 2015 | 166 | 0.350 |
Why?
| | Addison Disease | 6 | 2012 | 38 | 0.340 |
Why?
| | Major Histocompatibility Complex | 6 | 2026 | 233 | 0.340 |
Why?
| | Liver | 3 | 2012 | 1899 | 0.330 |
Why?
| | Fetal Blood | 6 | 2021 | 327 | 0.330 |
Why?
| | Adipocytes | 1 | 2012 | 223 | 0.330 |
Why?
| | Sex Factors | 20 | 2020 | 2110 | 0.330 |
Why?
| | Life Style | 5 | 2015 | 486 | 0.330 |
Why?
| | Hypolipidemic Agents | 2 | 2010 | 89 | 0.320 |
Why?
| | Dietary Proteins | 4 | 2019 | 135 | 0.320 |
Why?
| | Hypoglycemic Agents | 8 | 2020 | 1399 | 0.320 |
Why?
| | Evidence-Based Medicine | 1 | 2014 | 740 | 0.320 |
Why?
| | Cholesterol, HDL | 8 | 2015 | 201 | 0.320 |
Why?
| | Plant Proteins | 1 | 2011 | 111 | 0.310 |
Why?
| | Epidemics | 1 | 2011 | 96 | 0.310 |
Why?
| | Precision Medicine | 1 | 2014 | 461 | 0.310 |
Why?
| | Research | 2 | 2013 | 431 | 0.310 |
Why?
| | Eating | 5 | 2023 | 387 | 0.310 |
Why?
| | Surveys and Questionnaires | 17 | 2024 | 6085 | 0.310 |
Why?
| | Blood Proteins | 3 | 2017 | 239 | 0.300 |
Why?
| | Patient Education as Topic | 2 | 2005 | 777 | 0.300 |
Why?
| | Steroid 21-Hydroxylase | 5 | 2012 | 27 | 0.300 |
Why?
| | HLA-DQ beta-Chains | 12 | 2019 | 58 | 0.300 |
Why?
| | CTLA-4 Antigen | 5 | 2017 | 105 | 0.300 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2025 | 1146 | 0.300 |
Why?
| | Cystatin C | 6 | 2014 | 66 | 0.300 |
Why?
| | Cesarean Section | 2 | 2024 | 230 | 0.290 |
Why?
| | Obesity | 12 | 2015 | 3118 | 0.290 |
Why?
| | Family Health | 8 | 2017 | 191 | 0.290 |
Why?
| | Cytokines | 6 | 2026 | 2069 | 0.290 |
Why?
| | Multivariate Analysis | 10 | 2016 | 1547 | 0.290 |
Why?
| | Clinical Trials as Topic | 3 | 2009 | 1062 | 0.280 |
Why?
| | Sex Distribution | 6 | 2011 | 388 | 0.280 |
Why?
| | Diet, Ketogenic | 1 | 2009 | 39 | 0.280 |
Why?
| | Gastrointestinal Microbiome | 3 | 2025 | 768 | 0.280 |
Why?
| | Rotavirus | 2 | 2016 | 21 | 0.280 |
Why?
| | Feces | 7 | 2025 | 496 | 0.270 |
Why?
| | Reproductive History | 1 | 2008 | 12 | 0.270 |
Why?
| | Antigens, CD | 2 | 2009 | 558 | 0.270 |
Why?
| | Diabetes Mellitus | 8 | 2009 | 1101 | 0.270 |
Why?
| | Europe | 11 | 2021 | 421 | 0.270 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.260 |
Why?
| | Adiposity | 7 | 2020 | 532 | 0.260 |
Why?
| | Cystatins | 1 | 2007 | 7 | 0.260 |
Why?
| | Epigenesis, Genetic | 4 | 2026 | 693 | 0.260 |
Why?
| | Reference Values | 10 | 2012 | 798 | 0.260 |
Why?
| | Pregnancy | 18 | 2025 | 7215 | 0.260 |
Why?
| | Seroepidemiologic Studies | 4 | 2023 | 171 | 0.260 |
Why?
| | Carotenoids | 2 | 2026 | 47 | 0.250 |
Why?
| | Tomography, X-Ray Computed | 12 | 2018 | 2770 | 0.250 |
Why?
| | Diet, Gluten-Free | 3 | 2024 | 56 | 0.250 |
Why?
| | Gene-Environment Interaction | 5 | 2024 | 180 | 0.250 |
Why?
| | Proteome | 2 | 2025 | 513 | 0.250 |
Why?
| | Glycopeptides | 2 | 2018 | 45 | 0.250 |
Why?
| | Iron | 3 | 2023 | 359 | 0.250 |
Why?
| | Survival Analysis | 4 | 2021 | 1378 | 0.250 |
Why?
| | Adipose Tissue | 4 | 2018 | 645 | 0.250 |
Why?
| | HLA-DRB1 Chains | 8 | 2019 | 110 | 0.240 |
Why?
| | Patient Compliance | 3 | 2023 | 588 | 0.240 |
Why?
| | Metabolome | 2 | 2020 | 391 | 0.240 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 80 | 0.240 |
Why?
| | Rotavirus Infections | 1 | 2006 | 37 | 0.240 |
Why?
| | Histocompatibility Antigens Class I | 5 | 2011 | 202 | 0.240 |
Why?
| | RNA, Viral | 3 | 2019 | 692 | 0.240 |
Why?
| | Tocopherols | 1 | 2026 | 31 | 0.240 |
Why?
| | Exercise | 4 | 2023 | 2205 | 0.240 |
Why?
| | Apolipoproteins C | 1 | 2006 | 3 | 0.240 |
Why?
| | Remission Induction | 2 | 2004 | 306 | 0.240 |
Why?
| | HLA-DR alpha-Chains | 1 | 2026 | 5 | 0.240 |
Why?
| | Complement C4a | 1 | 2026 | 9 | 0.240 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 229 | 0.240 |
Why?
| | Vitamin A | 1 | 2026 | 62 | 0.240 |
Why?
| | Overweight | 3 | 2021 | 614 | 0.240 |
Why?
| | Regression Analysis | 15 | 2014 | 1001 | 0.240 |
Why?
| | Infant Formula | 3 | 2019 | 71 | 0.230 |
Why?
| | Thyroid Gland | 1 | 2026 | 91 | 0.230 |
Why?
| | Contraception | 1 | 2008 | 170 | 0.230 |
Why?
| | Protein Tyrosine Phosphatases | 7 | 2006 | 167 | 0.230 |
Why?
| | Receptors, Interleukin-2 | 1 | 2005 | 64 | 0.230 |
Why?
| | Cardiovascular Diseases | 8 | 2018 | 2191 | 0.230 |
Why?
| | Chromosome Mapping | 4 | 2025 | 507 | 0.230 |
Why?
| | Hypersensitivity, Immediate | 1 | 2025 | 41 | 0.230 |
Why?
| | Carotid Arteries | 5 | 1998 | 208 | 0.230 |
Why?
| | Quantitative Trait Loci | 2 | 2025 | 381 | 0.230 |
Why?
| | Gene Frequency | 10 | 2020 | 489 | 0.220 |
Why?
| | Maternal Age | 3 | 2004 | 128 | 0.220 |
Why?
| | Diet Records | 4 | 2019 | 89 | 0.220 |
Why?
| | Aged | 45 | 2021 | 26215 | 0.220 |
Why?
| | Proinsulin | 3 | 2014 | 54 | 0.220 |
Why?
| | Histocompatibility Antigens Class II | 5 | 2011 | 364 | 0.220 |
Why?
| | Tobacco Smoke Pollution | 4 | 2019 | 227 | 0.220 |
Why?
| | Glucose Intolerance | 7 | 2013 | 142 | 0.220 |
Why?
| | Plasminogen Activator Inhibitor 1 | 6 | 2017 | 85 | 0.220 |
Why?
| | Apolipoproteins | 3 | 2014 | 38 | 0.220 |
Why?
| | Introns | 1 | 2026 | 256 | 0.220 |
Why?
| | Mass Spectrometry | 4 | 2025 | 731 | 0.210 |
Why?
| | Linear Models | 7 | 2016 | 849 | 0.210 |
Why?
| | Abdominal Wall | 1 | 2004 | 28 | 0.210 |
Why?
| | Docosahexaenoic Acids | 3 | 2021 | 88 | 0.210 |
Why?
| | Health Surveys | 3 | 2018 | 520 | 0.210 |
Why?
| | Immunotherapy | 1 | 2009 | 667 | 0.210 |
Why?
| | Antihypertensive Agents | 2 | 2007 | 521 | 0.210 |
Why?
| | Hyperlipidemias | 1 | 2005 | 120 | 0.210 |
Why?
| | Immunoglobulin A | 6 | 2024 | 214 | 0.210 |
Why?
| | Iodide Peroxidase | 6 | 2026 | 35 | 0.200 |
Why?
| | Bone Density | 2 | 2020 | 487 | 0.200 |
Why?
| | Delivery, Obstetric | 2 | 2004 | 160 | 0.200 |
Why?
| | Fever | 1 | 2025 | 319 | 0.200 |
Why?
| | Vitamin B Complex | 1 | 2024 | 39 | 0.200 |
Why?
| | Seasons | 5 | 2024 | 538 | 0.200 |
Why?
| | Animals | 26 | 2022 | 38097 | 0.200 |
Why?
| | Coronary Angiography | 2 | 2014 | 328 | 0.200 |
Why?
| | Electrochemical Techniques | 2 | 2021 | 55 | 0.200 |
Why?
| | Peptide Library | 1 | 2024 | 91 | 0.200 |
Why?
| | Alanine Transaminase | 2 | 2015 | 151 | 0.200 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2026 | 849 | 0.200 |
Why?
| | Haptoglobins | 3 | 2013 | 71 | 0.200 |
Why?
| | Birth Weight | 4 | 2016 | 517 | 0.200 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 376 | 0.190 |
Why?
| | Iron Overload | 1 | 2023 | 19 | 0.190 |
Why?
| | Child Development | 2 | 2020 | 483 | 0.190 |
Why?
| | Extracellular Vesicles | 1 | 2025 | 171 | 0.190 |
Why?
| | Muscle, Skeletal | 2 | 2018 | 1791 | 0.190 |
Why?
| | Virus Diseases | 4 | 2021 | 216 | 0.190 |
Why?
| | ROC Curve | 4 | 2019 | 618 | 0.180 |
Why?
| | Ketone Bodies | 2 | 2014 | 16 | 0.180 |
Why?
| | Kaplan-Meier Estimate | 4 | 2018 | 971 | 0.180 |
Why?
| | Influenza, Human | 2 | 2022 | 624 | 0.180 |
Why?
| | Alcohol Drinking | 1 | 2009 | 843 | 0.180 |
Why?
| | Costs and Cost Analysis | 2 | 2020 | 221 | 0.180 |
Why?
| | Complement System Proteins | 1 | 2025 | 314 | 0.180 |
Why?
| | Mothers | 4 | 2021 | 765 | 0.180 |
Why?
| | Diabetic Retinopathy | 4 | 2016 | 209 | 0.180 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 444 | 0.180 |
Why?
| | Pediatrics | 4 | 2020 | 1125 | 0.180 |
Why?
| | Lipid Metabolism | 2 | 2019 | 529 | 0.180 |
Why?
| | Maternal Nutritional Physiological Phenomena | 2 | 2021 | 178 | 0.180 |
Why?
| | Peptides | 3 | 2024 | 998 | 0.170 |
Why?
| | Bacteria | 2 | 2025 | 766 | 0.170 |
Why?
| | T-Lymphocytes | 3 | 2025 | 1997 | 0.170 |
Why?
| | Blood Pressure | 9 | 2014 | 1782 | 0.170 |
Why?
| | Age Distribution | 5 | 2011 | 404 | 0.170 |
Why?
| | Odds Ratio | 6 | 2015 | 1083 | 0.170 |
Why?
| | Parents | 6 | 2023 | 1407 | 0.170 |
Why?
| | Lipase | 1 | 2002 | 75 | 0.170 |
Why?
| | Dietary Approaches To Stop Hypertension | 1 | 2021 | 13 | 0.170 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2021 | 49 | 0.170 |
Why?
| | Monitoring, Ambulatory | 2 | 2014 | 89 | 0.170 |
Why?
| | Glycerol | 2 | 2012 | 90 | 0.170 |
Why?
| | Reproducibility of Results | 9 | 2021 | 3416 | 0.170 |
Why?
| | Receptors, Calcitriol | 2 | 2012 | 56 | 0.170 |
Why?
| | Growth | 2 | 2016 | 49 | 0.170 |
Why?
| | Promoter Regions, Genetic | 2 | 2006 | 1247 | 0.170 |
Why?
| | Body Height | 3 | 2014 | 203 | 0.170 |
Why?
| | White Matter | 1 | 2023 | 155 | 0.170 |
Why?
| | Polysaccharides | 2 | 2022 | 86 | 0.170 |
Why?
| | Gastroenteritis | 2 | 2016 | 63 | 0.160 |
Why?
| | Gestational Age | 3 | 2020 | 989 | 0.160 |
Why?
| | F2-Isoprostanes | 2 | 2015 | 21 | 0.160 |
Why?
| | Luminescence | 3 | 2016 | 37 | 0.160 |
Why?
| | B-Lymphocytes | 1 | 2026 | 872 | 0.160 |
Why?
| | HLA-B8 Antigen | 4 | 2012 | 11 | 0.160 |
Why?
| | Ketosis | 1 | 2020 | 12 | 0.160 |
Why?
| | Influenza Vaccines | 2 | 2017 | 534 | 0.160 |
Why?
| | Vitamins | 2 | 2020 | 184 | 0.160 |
Why?
| | Neutrophils | 1 | 2026 | 1125 | 0.160 |
Why?
| | Genomics | 2 | 2021 | 830 | 0.160 |
Why?
| | Disease Susceptibility | 6 | 2020 | 344 | 0.160 |
Why?
| | Dietary Carbohydrates | 2 | 2015 | 147 | 0.160 |
Why?
| | Dietary Sucrose | 1 | 2020 | 50 | 0.150 |
Why?
| | Neonatal Screening | 4 | 2020 | 179 | 0.150 |
Why?
| | Biopsy | 5 | 2017 | 1082 | 0.150 |
Why?
| | Mannose | 1 | 2019 | 23 | 0.150 |
Why?
| | Sugars | 1 | 2020 | 40 | 0.150 |
Why?
| | Prodromal Symptoms | 1 | 2020 | 20 | 0.150 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 125 | 0.150 |
Why?
| | Life Change Events | 1 | 2021 | 147 | 0.150 |
Why?
| | Mice, Inbred NOD | 5 | 2015 | 616 | 0.150 |
Why?
| | Energy Intake | 5 | 2023 | 512 | 0.150 |
Why?
| | Interferon-gamma | 2 | 2021 | 784 | 0.150 |
Why?
| | Adenosine Diphosphate | 1 | 2019 | 83 | 0.150 |
Why?
| | Phospholipids | 1 | 2021 | 214 | 0.150 |
Why?
| | Kidney | 2 | 2018 | 1496 | 0.150 |
Why?
| | Metabolic Clearance Rate | 3 | 2014 | 115 | 0.150 |
Why?
| | Developing Countries | 2 | 1993 | 317 | 0.150 |
Why?
| | Oxidative Stress | 3 | 2017 | 1359 | 0.150 |
Why?
| | Epidemiologic Methods | 4 | 2014 | 91 | 0.150 |
Why?
| | Cation Transport Proteins | 3 | 2011 | 118 | 0.150 |
Why?
| | Measles | 1 | 2019 | 46 | 0.150 |
Why?
| | Apolipoproteins B | 2 | 2015 | 47 | 0.140 |
Why?
| | Osteoporotic Fractures | 1 | 2020 | 62 | 0.140 |
Why?
| | Glycosuria | 2 | 2009 | 10 | 0.140 |
Why?
| | Fatty Acids, Omega-6 | 4 | 2020 | 47 | 0.140 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2003 | 440 | 0.140 |
Why?
| | Butyrates | 1 | 2019 | 66 | 0.140 |
Why?
| | Antibodies, Bacterial | 1 | 2019 | 147 | 0.140 |
Why?
| | Cotinine | 1 | 2019 | 77 | 0.140 |
Why?
| | Genes, MHC Class II | 3 | 2012 | 77 | 0.140 |
Why?
| | Uromodulin | 1 | 2018 | 22 | 0.140 |
Why?
| | Genetic Markers | 4 | 2013 | 338 | 0.140 |
Why?
| | Cholesterol | 5 | 2014 | 408 | 0.140 |
Why?
| | Models, Biological | 5 | 2019 | 1764 | 0.140 |
Why?
| | Hypersensitivity | 1 | 2021 | 254 | 0.140 |
Why?
| | Mexican Americans | 3 | 2014 | 119 | 0.140 |
Why?
| | Health Expenditures | 1 | 2020 | 194 | 0.140 |
Why?
| | HLA-DP beta-Chains | 3 | 2015 | 88 | 0.140 |
Why?
| | Self Report | 3 | 2020 | 876 | 0.130 |
Why?
| | Amino Acid Sequence | 6 | 2024 | 2131 | 0.130 |
Why?
| | HLA-DR2 Antigen | 2 | 2012 | 8 | 0.130 |
Why?
| | Squalene | 1 | 2017 | 9 | 0.130 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2017 | 18 | 0.130 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 48 | 0.130 |
Why?
| | Phenotype | 8 | 2024 | 3170 | 0.130 |
Why?
| | Immunization | 1 | 1999 | 375 | 0.130 |
Why?
| | Antipyretics | 1 | 2017 | 5 | 0.130 |
Why?
| | High-Throughput Screening Assays | 1 | 2019 | 177 | 0.130 |
Why?
| | Gene Expression Profiling | 5 | 2017 | 1777 | 0.130 |
Why?
| | Cost of Illness | 1 | 2020 | 324 | 0.130 |
Why?
| | Immunologic Memory | 1 | 2019 | 368 | 0.130 |
Why?
| | Radioimmunoassay | 6 | 2016 | 165 | 0.130 |
Why?
| | Models, Genetic | 2 | 2017 | 527 | 0.130 |
Why?
| | Blood Cell Count | 1 | 2017 | 55 | 0.130 |
Why?
| | Feeding Behavior | 3 | 2013 | 692 | 0.130 |
Why?
| | Body Composition | 3 | 2020 | 693 | 0.130 |
Why?
| | Rheumatoid Factor | 3 | 2007 | 178 | 0.130 |
Why?
| | Immune Tolerance | 1 | 2019 | 385 | 0.130 |
Why?
| | Osteoporosis | 1 | 2020 | 239 | 0.130 |
Why?
| | Genetic Loci | 3 | 2015 | 267 | 0.130 |
Why?
| | Kidney Diseases | 2 | 2012 | 426 | 0.130 |
Why?
| | Rural Health | 2 | 2002 | 87 | 0.120 |
Why?
| | Prenatal Nutritional Physiological Phenomena | 1 | 2017 | 55 | 0.120 |
Why?
| | Poland | 4 | 2010 | 34 | 0.120 |
Why?
| | Models, Theoretical | 2 | 2017 | 560 | 0.120 |
Why?
| | Milk Proteins | 1 | 1996 | 33 | 0.120 |
Why?
| | Body Weight | 3 | 2016 | 972 | 0.120 |
Why?
| | Toxins, Biological | 1 | 2016 | 12 | 0.120 |
Why?
| | Homozygote | 5 | 2014 | 199 | 0.120 |
Why?
| | Arachidonic Acid | 2 | 2021 | 102 | 0.120 |
Why?
| | Immunoglobulin G | 4 | 2021 | 892 | 0.120 |
Why?
| | Proteins | 2 | 2021 | 1023 | 0.120 |
Why?
| | Patient Care Planning | 2 | 2015 | 170 | 0.120 |
Why?
| | Hygiene | 1 | 2016 | 29 | 0.120 |
Why?
| | Vitamin B 12 | 1 | 2017 | 135 | 0.120 |
Why?
| | HLA-A1 Antigen | 2 | 2006 | 3 | 0.120 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 7 | 2006 | 44 | 0.120 |
Why?
| | HLA-DP Antigens | 2 | 2007 | 32 | 0.120 |
Why?
| | Diet Surveys | 4 | 2021 | 90 | 0.120 |
Why?
| | Anorexia Nervosa | 1 | 2017 | 79 | 0.120 |
Why?
| | Polymerase Chain Reaction | 5 | 2011 | 1043 | 0.120 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2017 | 128 | 0.110 |
Why?
| | Lentigo | 1 | 2015 | 6 | 0.110 |
Why?
| | Feeding Methods | 1 | 2015 | 5 | 0.110 |
Why?
| | Oligonucleotide Array Sequence Analysis | 4 | 2011 | 751 | 0.110 |
Why?
| | Practice Guidelines as Topic | 1 | 2023 | 1582 | 0.110 |
Why?
| | Histocompatibility Testing | 6 | 2017 | 123 | 0.110 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2022 | 534 | 0.110 |
Why?
| | Stress, Psychological | 2 | 2021 | 1149 | 0.110 |
Why?
| | Medical Records | 2 | 2007 | 192 | 0.110 |
Why?
| | Absorptiometry, Photon | 2 | 2020 | 277 | 0.110 |
Why?
| | Complement C3 | 1 | 2016 | 187 | 0.110 |
Why?
| | Genetic Association Studies | 4 | 2020 | 371 | 0.110 |
Why?
| | Carbohydrates | 1 | 2015 | 66 | 0.110 |
Why?
| | Dietary Fiber | 1 | 2015 | 59 | 0.110 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2018 | 668 | 0.110 |
Why?
| | Oxygen | 1 | 2020 | 981 | 0.110 |
Why?
| | Child Day Care Centers | 1 | 2015 | 44 | 0.110 |
Why?
| | Erythrocytes | 1 | 2021 | 749 | 0.110 |
Why?
| | Up-Regulation | 2 | 2016 | 848 | 0.110 |
Why?
| | Periodontal Diseases | 1 | 2015 | 62 | 0.110 |
Why?
| | International Agencies | 1 | 2014 | 30 | 0.110 |
Why?
| | Fructosamine | 1 | 2014 | 11 | 0.110 |
Why?
| | Gram-Positive Bacteria | 1 | 2014 | 48 | 0.110 |
Why?
| | Health Records, Personal | 1 | 2014 | 26 | 0.110 |
Why?
| | Dairy Products | 1 | 2014 | 30 | 0.110 |
Why?
| | Video Recording | 2 | 2015 | 219 | 0.110 |
Why?
| | Genetic Linkage | 2 | 2015 | 273 | 0.110 |
Why?
| | Adolescent Medicine | 1 | 2014 | 26 | 0.100 |
Why?
| | Carotid Artery Diseases | 3 | 2000 | 70 | 0.100 |
Why?
| | Molecular Sequence Data | 7 | 2015 | 2883 | 0.100 |
Why?
| | Societies, Scientific | 1 | 2014 | 50 | 0.100 |
Why?
| | Acetaminophen | 1 | 2017 | 267 | 0.100 |
Why?
| | Gram-Negative Bacteria | 1 | 2014 | 80 | 0.100 |
Why?
| | Bias | 1 | 2015 | 197 | 0.100 |
Why?
| | Renal Insufficiency | 1 | 2016 | 172 | 0.100 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 346 | 0.100 |
Why?
| | Eicosapentaenoic Acid | 1 | 2013 | 37 | 0.100 |
Why?
| | Cholesterol, Dietary | 1 | 2013 | 15 | 0.100 |
Why?
| | Gene Expression | 3 | 2021 | 1478 | 0.100 |
Why?
| | Hemodynamics | 1 | 2018 | 1118 | 0.100 |
Why?
| | Siblings | 3 | 2018 | 196 | 0.100 |
Why?
| | Eggs | 1 | 2013 | 25 | 0.100 |
Why?
| | Phosphates | 1 | 2014 | 177 | 0.100 |
Why?
| | Creatinine | 4 | 2018 | 515 | 0.100 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2023 | 673 | 0.090 |
Why?
| | Research Support as Topic | 1 | 2013 | 81 | 0.090 |
Why?
| | Tumor Suppressor Proteins | 1 | 2015 | 322 | 0.090 |
Why?
| | Heart Rate | 3 | 2010 | 856 | 0.090 |
Why?
| | Mice | 11 | 2022 | 18355 | 0.090 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2012 | 13 | 0.090 |
Why?
| | Hypoxia | 1 | 2020 | 1199 | 0.090 |
Why?
| | Communicable Diseases | 1 | 2015 | 166 | 0.090 |
Why?
| | Monoamine Oxidase | 1 | 2012 | 27 | 0.090 |
Why?
| | Organizational Innovation | 1 | 2013 | 119 | 0.090 |
Why?
| | Biological Specimen Banks | 1 | 2013 | 118 | 0.090 |
Why?
| | Immunity, Innate | 2 | 2022 | 835 | 0.090 |
Why?
| | Anesthesiology | 1 | 2015 | 179 | 0.090 |
Why?
| | Chromosomes, Human, Pair 2 | 2 | 2009 | 28 | 0.090 |
Why?
| | History, 21st Century | 1 | 2013 | 222 | 0.090 |
Why?
| | Sex Characteristics | 7 | 2015 | 789 | 0.090 |
Why?
| | Stomach | 1 | 2012 | 111 | 0.090 |
Why?
| | Epistasis, Genetic | 1 | 2012 | 64 | 0.090 |
Why?
| | CpG Islands | 2 | 2023 | 171 | 0.090 |
Why?
| | Interleukin-4 | 2 | 2005 | 207 | 0.090 |
Why?
| | Lymphocytes | 1 | 2014 | 376 | 0.090 |
Why?
| | Pilot Projects | 4 | 2023 | 1897 | 0.090 |
Why?
| | History, 20th Century | 1 | 2013 | 328 | 0.090 |
Why?
| | Specimen Handling | 1 | 2013 | 183 | 0.090 |
Why?
| | Histocompatibility Antigens | 2 | 2013 | 102 | 0.090 |
Why?
| | Nuclear Family | 2 | 2009 | 50 | 0.090 |
Why?
| | Intestine, Small | 2 | 2005 | 167 | 0.090 |
Why?
| | Hyperinsulinism | 2 | 2010 | 115 | 0.090 |
Why?
| | Intestines | 1 | 2014 | 354 | 0.090 |
Why?
| | Calcifediol | 1 | 2011 | 31 | 0.090 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2016 | 910 | 0.090 |
Why?
| | Pedigree | 4 | 2017 | 515 | 0.090 |
Why?
| | Gliadin | 2 | 2009 | 13 | 0.080 |
Why?
| | Combined Modality Therapy | 1 | 2014 | 1270 | 0.080 |
Why?
| | Primary Prevention | 1 | 2013 | 222 | 0.080 |
Why?
| | Patient Selection | 3 | 2011 | 739 | 0.080 |
Why?
| | Toll-Like Receptors | 1 | 2012 | 193 | 0.080 |
Why?
| | Vaccines | 1 | 2016 | 389 | 0.080 |
Why?
| | Interleukin-2 | 1 | 2012 | 440 | 0.080 |
Why?
| | HLA-B Antigens | 1 | 2011 | 58 | 0.080 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2011 | 24 | 0.080 |
Why?
| | Kidney Function Tests | 1 | 2011 | 156 | 0.080 |
Why?
| | Vitamin D-Binding Protein | 1 | 2010 | 16 | 0.080 |
Why?
| | Viruses | 1 | 2013 | 166 | 0.080 |
Why?
| | Thyroglobulin | 3 | 2025 | 29 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2017 | 2028 | 0.080 |
Why?
| | Vascular Diseases | 2 | 2013 | 252 | 0.080 |
Why?
| | Endocrine Cells | 1 | 2010 | 6 | 0.080 |
Why?
| | Food, Fortified | 1 | 2010 | 44 | 0.080 |
Why?
| | Weight Gain | 2 | 2011 | 561 | 0.080 |
Why?
| | Linkage Disequilibrium | 4 | 2015 | 255 | 0.080 |
Why?
| | Microbiota | 2 | 2014 | 730 | 0.080 |
Why?
| | Gastrointestinal Diseases | 1 | 2012 | 222 | 0.080 |
Why?
| | Interleukin-1beta | 1 | 2012 | 389 | 0.080 |
Why?
| | Milk, Human | 3 | 2018 | 175 | 0.080 |
Why?
| | Nutrition Assessment | 2 | 2015 | 90 | 0.080 |
Why?
| | Lymphocyte Activation | 1 | 2014 | 1133 | 0.080 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2010 | 154 | 0.080 |
Why?
| | Decision Support Techniques | 2 | 2013 | 480 | 0.080 |
Why?
| | Leukocytes, Mononuclear | 2 | 2012 | 574 | 0.080 |
Why?
| | Myocardial Infarction | 2 | 1994 | 1211 | 0.080 |
Why?
| | RNA | 1 | 2016 | 912 | 0.080 |
Why?
| | Abdomen | 1 | 2010 | 142 | 0.080 |
Why?
| | Monitoring, Immunologic | 1 | 2009 | 25 | 0.080 |
Why?
| | Socioeconomic Factors | 5 | 2017 | 1327 | 0.080 |
Why?
| | Membrane Proteins | 3 | 2002 | 1166 | 0.070 |
Why?
| | Feasibility Studies | 3 | 2026 | 1115 | 0.070 |
Why?
| | Family | 5 | 2018 | 685 | 0.070 |
Why?
| | Quality Control | 3 | 2013 | 161 | 0.070 |
Why?
| | Transcription Factors | 1 | 2017 | 1736 | 0.070 |
Why?
| | Waist-Hip Ratio | 2 | 2009 | 37 | 0.070 |
Why?
| | Pancreas | 2 | 2023 | 341 | 0.070 |
Why?
| | Sequence Analysis, DNA | 3 | 2011 | 778 | 0.070 |
Why?
| | Metabolic Syndrome | 1 | 2013 | 361 | 0.070 |
Why?
| | Bifidobacterium | 2 | 2018 | 21 | 0.070 |
Why?
| | Homeostasis | 2 | 2010 | 644 | 0.070 |
Why?
| | Antigens, Viral | 2 | 2021 | 182 | 0.070 |
Why?
| | Isoenzymes | 2 | 2006 | 295 | 0.070 |
Why?
| | Proteinuria | 1 | 2009 | 104 | 0.070 |
Why?
| | Glycemic Index | 1 | 2008 | 26 | 0.070 |
Why?
| | Algorithms | 3 | 2026 | 1850 | 0.070 |
Why?
| | Spleen | 1 | 2010 | 508 | 0.070 |
Why?
| | Magnetic Resonance Spectroscopy | 3 | 2016 | 627 | 0.070 |
Why?
| | DEAD-box RNA Helicases | 1 | 2008 | 84 | 0.070 |
Why?
| | Environmental Monitoring | 1 | 2010 | 347 | 0.070 |
Why?
| | Interleukin-6 | 1 | 2012 | 779 | 0.070 |
Why?
| | Laboratories | 1 | 2009 | 110 | 0.070 |
Why?
| | Telomere | 3 | 2022 | 287 | 0.070 |
Why?
| | Disease Outbreaks | 2 | 1991 | 419 | 0.060 |
Why?
| | Antibody Formation | 1 | 2008 | 288 | 0.060 |
Why?
| | Angiotensins | 1 | 2007 | 8 | 0.060 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2007 | 25 | 0.060 |
Why?
| | Lipoproteins, LDL | 2 | 2008 | 119 | 0.060 |
Why?
| | Contraceptive Agents, Female | 1 | 2008 | 80 | 0.060 |
Why?
| | Clinical Competence | 1 | 2015 | 1247 | 0.060 |
Why?
| | Clinical Laboratory Techniques | 1 | 2007 | 96 | 0.060 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2007 | 56 | 0.060 |
Why?
| | Tandem Mass Spectrometry | 2 | 2021 | 572 | 0.060 |
Why?
| | Antidepressive Agents | 1 | 2009 | 242 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 1925 | 0.060 |
Why?
| | Datasets as Topic | 2 | 2018 | 118 | 0.060 |
Why?
| | Drug Utilization | 2 | 2017 | 168 | 0.060 |
Why?
| | Wheat Hypersensitivity | 1 | 2006 | 4 | 0.060 |
Why?
| | Insulin Infusion Systems | 2 | 2017 | 480 | 0.060 |
Why?
| | Microsatellite Repeats | 2 | 2009 | 157 | 0.060 |
Why?
| | Population Surveillance | 3 | 2020 | 484 | 0.060 |
Why?
| | Physicians | 1 | 2015 | 956 | 0.060 |
Why?
| | Pediatric Obesity | 1 | 2014 | 638 | 0.060 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 2006 | 30 | 0.060 |
Why?
| | Antibody Specificity | 4 | 2011 | 179 | 0.060 |
Why?
| | Apolipoprotein C-III | 1 | 2006 | 11 | 0.060 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2018 | 532 | 0.060 |
Why?
| | Epitope Mapping | 2 | 2024 | 61 | 0.060 |
Why?
| | Birth Order | 2 | 2004 | 14 | 0.060 |
Why?
| | Adenovirus Infections, Human | 1 | 2005 | 15 | 0.060 |
Why?
| | Metagenomics | 2 | 2019 | 149 | 0.060 |
Why?
| | Neoplasm Proteins | 2 | 2020 | 442 | 0.060 |
Why?
| | Paired Box Transcription Factors | 1 | 2005 | 43 | 0.060 |
Why?
| | Carrier State | 1 | 2006 | 78 | 0.060 |
Why?
| | Adenoviruses, Human | 1 | 2005 | 26 | 0.060 |
Why?
| | Receptors, Interleukin-4 | 1 | 2005 | 16 | 0.060 |
Why?
| | Chronic Disease | 4 | 2017 | 1812 | 0.060 |
Why?
| | Statistics, Nonparametric | 2 | 2011 | 428 | 0.060 |
Why?
| | Codon, Terminator | 1 | 2005 | 25 | 0.060 |
Why?
| | Chromatography, Liquid | 3 | 2012 | 450 | 0.060 |
Why?
| | Matrix Metalloproteinases | 1 | 2026 | 95 | 0.060 |
Why?
| | Antigens, Differentiation | 1 | 2005 | 76 | 0.060 |
Why?
| | Amino Acid Substitution | 1 | 2006 | 302 | 0.060 |
Why?
| | Health Plan Implementation | 1 | 2026 | 141 | 0.060 |
Why?
| | Codon, Nonsense | 1 | 2005 | 45 | 0.050 |
Why?
| | Capsid Proteins | 1 | 2005 | 94 | 0.050 |
Why?
| | Protective Factors | 2 | 2015 | 99 | 0.050 |
Why?
| | Safety-net Providers | 1 | 2026 | 130 | 0.050 |
Why?
| | Fathers | 1 | 2005 | 53 | 0.050 |
Why?
| | Interleukin-13 | 1 | 2005 | 146 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2018 | 508 | 0.050 |
Why?
| | Radiography, Abdominal | 1 | 2004 | 44 | 0.050 |
Why?
| | Cattle | 3 | 2017 | 946 | 0.050 |
Why?
| | Norway | 2 | 2019 | 41 | 0.050 |
Why?
| | Research Design | 3 | 2019 | 1139 | 0.050 |
Why?
| | CD3 Complex | 1 | 2024 | 112 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2018 | 4568 | 0.050 |
Why?
| | Survivors | 1 | 2008 | 523 | 0.050 |
Why?
| | Nutritional Status | 1 | 2007 | 353 | 0.050 |
Why?
| | Arthritis, Juvenile | 1 | 2005 | 60 | 0.050 |
Why?
| | Metagenome | 1 | 2025 | 126 | 0.050 |
Why?
| | Anthropometry | 1 | 2004 | 206 | 0.050 |
Why?
| | Transcriptome | 2 | 2023 | 1042 | 0.050 |
Why?
| | Pennsylvania | 2 | 2018 | 138 | 0.050 |
Why?
| | Waist Circumference | 2 | 2015 | 143 | 0.050 |
Why?
| | Postmenopause | 3 | 2020 | 394 | 0.050 |
Why?
| | DNA | 2 | 2011 | 1437 | 0.050 |
Why?
| | Insulin, Isophane | 1 | 2003 | 22 | 0.050 |
Why?
| | Cross-Cultural Comparison | 2 | 2015 | 84 | 0.050 |
Why?
| | Confidence Intervals | 1 | 2004 | 330 | 0.050 |
Why?
| | Registries | 7 | 2019 | 2410 | 0.050 |
Why?
| | International Cooperation | 3 | 2016 | 197 | 0.050 |
Why?
| | GTPase-Activating Proteins | 1 | 2023 | 81 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2022 | 334 | 0.050 |
Why?
| | Computer Simulation | 2 | 2026 | 1003 | 0.050 |
Why?
| | Iron, Dietary | 1 | 2023 | 23 | 0.050 |
Why?
| | Aspartic Acid | 1 | 2023 | 88 | 0.050 |
Why?
| | Peptides, Cyclic | 1 | 2005 | 273 | 0.050 |
Why?
| | Creatine | 1 | 2023 | 63 | 0.050 |
Why?
| | Glycomics | 1 | 2022 | 7 | 0.050 |
Why?
| | Biomedical Research | 1 | 2009 | 719 | 0.050 |
Why?
| | Markov Chains | 2 | 2020 | 132 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2023 | 134 | 0.050 |
Why?
| | Observer Variation | 2 | 2015 | 357 | 0.050 |
Why?
| | HLA-DQ alpha-Chains | 2 | 2019 | 17 | 0.050 |
Why?
| | Renal Dialysis | 1 | 2006 | 466 | 0.050 |
Why?
| | Mice, Knockout | 1 | 2009 | 3130 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2026 | 309 | 0.040 |
Why?
| | Electrocardiography | 2 | 2010 | 668 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2025 | 473 | 0.040 |
Why?
| | Choline | 1 | 2023 | 138 | 0.040 |
Why?
| | Candida | 1 | 2022 | 46 | 0.040 |
Why?
| | HLA-B15 Antigen | 2 | 2012 | 12 | 0.040 |
Why?
| | Insulins | 1 | 2022 | 39 | 0.040 |
Why?
| | Prenatal Care | 1 | 2004 | 309 | 0.040 |
Why?
| | Homeodomain Proteins | 1 | 2005 | 523 | 0.040 |
Why?
| | Electrochemistry | 1 | 2021 | 70 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 413 | 0.040 |
Why?
| | Epitopes, B-Lymphocyte | 1 | 2021 | 20 | 0.040 |
Why?
| | Fungi | 1 | 2022 | 121 | 0.040 |
Why?
| | Diagnostic Techniques, Radioisotope | 1 | 2021 | 9 | 0.040 |
Why?
| | Linoleic Acid | 1 | 2021 | 44 | 0.040 |
Why?
| | Immunoglobulin D | 1 | 2021 | 29 | 0.040 |
Why?
| | China | 1 | 2021 | 273 | 0.040 |
Why?
| | Serologic Tests | 1 | 2021 | 54 | 0.040 |
Why?
| | Protein Interaction Mapping | 1 | 2021 | 105 | 0.040 |
Why?
| | p-Aminohippuric Acid | 1 | 2020 | 5 | 0.040 |
Why?
| | Perception | 1 | 2023 | 378 | 0.040 |
Why?
| | Pregnancy Trimester, Third | 1 | 2021 | 119 | 0.040 |
Why?
| | Retrospective Studies | 5 | 2025 | 17325 | 0.040 |
Why?
| | Iohexol | 1 | 2020 | 23 | 0.040 |
Why?
| | Furosemide | 1 | 2020 | 37 | 0.040 |
Why?
| | Isotopes | 1 | 2020 | 33 | 0.040 |
Why?
| | Drug Administration Schedule | 2 | 2017 | 782 | 0.040 |
Why?
| | Dehydroascorbic Acid | 1 | 2020 | 6 | 0.040 |
Why?
| | Drug Discovery | 1 | 2021 | 153 | 0.040 |
Why?
| | Models, Statistical | 3 | 2015 | 672 | 0.040 |
Why?
| | Antibodies, Heterophile | 1 | 1999 | 12 | 0.040 |
Why?
| | Antibody Diversity | 1 | 2019 | 16 | 0.040 |
Why?
| | Amino Acids, Branched-Chain | 1 | 2020 | 39 | 0.040 |
Why?
| | Kidney Transplantation | 1 | 2006 | 712 | 0.040 |
Why?
| | Glucose Transporter Type 2 | 1 | 2019 | 16 | 0.040 |
Why?
| | Viral Proteins | 2 | 2006 | 350 | 0.040 |
Why?
| | Peroxidase | 1 | 2020 | 168 | 0.040 |
Why?
| | Growth Charts | 1 | 2020 | 20 | 0.040 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 129 | 0.040 |
Why?
| | Haemophilus influenzae type b | 1 | 1999 | 12 | 0.040 |
Why?
| | Diphtheria-Tetanus-Pertussis Vaccine | 1 | 1999 | 28 | 0.040 |
Why?
| | Femur Neck | 1 | 2020 | 62 | 0.040 |
Why?
| | Salaries and Fringe Benefits | 1 | 2020 | 58 | 0.040 |
Why?
| | Phosphatidylethanolamines | 1 | 2020 | 77 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2023 | 592 | 0.040 |
Why?
| | Haemophilus Vaccines | 1 | 1999 | 29 | 0.040 |
Why?
| | Gastrointestinal Tract | 1 | 2022 | 204 | 0.040 |
Why?
| | Measles-Mumps-Rubella Vaccine | 1 | 2019 | 48 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2020 | 178 | 0.040 |
Why?
| | Poliovirus Vaccine, Inactivated | 1 | 1999 | 27 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2021 | 265 | 0.040 |
Why?
| | Proline | 1 | 2020 | 82 | 0.040 |
Why?
| | Pediatricians | 1 | 2020 | 121 | 0.040 |
Why?
| | Chromatography, Reverse-Phase | 1 | 2019 | 27 | 0.040 |
Why?
| | Hepatitis B Vaccines | 1 | 1999 | 43 | 0.040 |
Why?
| | Efficiency | 1 | 2020 | 103 | 0.040 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2019 | 125 | 0.040 |
Why?
| | Methionine | 1 | 2020 | 161 | 0.040 |
Why?
| | Immunoglobulin E | 1 | 2021 | 315 | 0.040 |
Why?
| | Texas | 2 | 2014 | 273 | 0.040 |
Why?
| | Macaca mulatta | 1 | 2019 | 186 | 0.040 |
Why?
| | Depression | 1 | 2009 | 1557 | 0.040 |
Why?
| | Alanine | 1 | 2020 | 169 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2021 | 421 | 0.040 |
Why?
| | Receptor, Insulin | 1 | 1999 | 93 | 0.040 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2021 | 592 | 0.040 |
Why?
| | Proteobacteria | 1 | 2018 | 16 | 0.040 |
Why?
| | Maternal Behavior | 1 | 1999 | 84 | 0.040 |
Why?
| | Machine Learning | 1 | 2025 | 587 | 0.040 |
Why?
| | Adenoviridae | 1 | 2019 | 199 | 0.040 |
Why?
| | beta 2-Microglobulin | 1 | 2018 | 48 | 0.040 |
Why?
| | Phosphoproteins | 1 | 2021 | 337 | 0.040 |
Why?
| | Down-Regulation | 1 | 2021 | 618 | 0.040 |
Why?
| | Pets | 1 | 2018 | 28 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2021 | 318 | 0.030 |
Why?
| | Emotional Adjustment | 1 | 2018 | 18 | 0.030 |
Why?
| | Lipocalin-2 | 1 | 2018 | 80 | 0.030 |
Why?
| | Interleukins | 1 | 2020 | 248 | 0.030 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 30 | 0.030 |
Why?
| | Fatty Acids, Volatile | 1 | 2018 | 60 | 0.030 |
Why?
| | Alternative Splicing | 1 | 2000 | 248 | 0.030 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2020 | 194 | 0.030 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 43 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2021 | 440 | 0.030 |
Why?
| | Postpartum Period | 1 | 2021 | 373 | 0.030 |
Why?
| | Lumbar Vertebrae | 1 | 2020 | 252 | 0.030 |
Why?
| | Osmolar Concentration | 1 | 2018 | 168 | 0.030 |
Why?
| | Employment | 1 | 2020 | 184 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2933 | 0.030 |
Why?
| | Pelvic Bones | 1 | 2020 | 134 | 0.030 |
Why?
| | Apolipoprotein A-I | 1 | 1997 | 39 | 0.030 |
Why?
| | Loss of Function Mutation | 1 | 2017 | 45 | 0.030 |
Why?
| | Estrogen Replacement Therapy | 1 | 1998 | 143 | 0.030 |
Why?
| | Discriminant Analysis | 1 | 2017 | 35 | 0.030 |
Why?
| | Collagen | 1 | 2020 | 457 | 0.030 |
Why?
| | Bicarbonates | 1 | 2017 | 45 | 0.030 |
Why?
| | Vascular Resistance | 1 | 2018 | 370 | 0.030 |
Why?
| | Canada | 1 | 2018 | 432 | 0.030 |
Why?
| | Vitamin E | 1 | 1997 | 125 | 0.030 |
Why?
| | Biopsy, Needle | 2 | 2011 | 185 | 0.030 |
Why?
| | Galactosamine | 1 | 2016 | 3 | 0.030 |
Why?
| | Receptor, ErbB-3 | 1 | 2017 | 48 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2018 | 501 | 0.030 |
Why?
| | Lipoprotein(a) | 1 | 1997 | 69 | 0.030 |
Why?
| | Acetylglucosamine | 1 | 2016 | 13 | 0.030 |
Why?
| | Molecular Weight | 2 | 2012 | 312 | 0.030 |
Why?
| | Longevity | 1 | 2018 | 178 | 0.030 |
Why?
| | Random Allocation | 1 | 2018 | 365 | 0.030 |
Why?
| | United Kingdom | 1 | 2018 | 358 | 0.030 |
Why?
| | Rotavirus Vaccines | 1 | 2016 | 39 | 0.030 |
Why?
| | Africa | 2 | 1996 | 119 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 653 | 0.030 |
Why?
| | Regional Blood Flow | 1 | 2018 | 514 | 0.030 |
Why?
| | Endpoint Determination | 1 | 2017 | 85 | 0.030 |
Why?
| | Anxiety | 1 | 2023 | 1122 | 0.030 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2017 | 159 | 0.030 |
Why?
| | Vitreoretinopathy, Proliferative | 1 | 2016 | 15 | 0.030 |
Why?
| | Antibody Affinity | 1 | 2016 | 60 | 0.030 |
Why?
| | Protein Domains | 1 | 2017 | 311 | 0.030 |
Why?
| | Genetic Background | 1 | 2015 | 16 | 0.030 |
Why?
| | Organ Specificity | 2 | 2007 | 309 | 0.030 |
Why?
| | Anemia, Sickle Cell | 1 | 2000 | 318 | 0.030 |
Why?
| | Mice, Inbred BALB C | 2 | 2013 | 1261 | 0.030 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2015 | 82 | 0.030 |
Why?
| | Analysis of Variance | 3 | 2010 | 1300 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2017 | 770 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 1998 | 499 | 0.030 |
Why?
| | Georgia | 1 | 2015 | 79 | 0.030 |
Why?
| | DNA Primers | 1 | 1996 | 505 | 0.030 |
Why?
| | Genes | 1 | 1995 | 228 | 0.030 |
Why?
| | Radioligand Assay | 2 | 2009 | 36 | 0.030 |
Why?
| | Florida | 1 | 2015 | 117 | 0.030 |
Why?
| | Heterozygote | 1 | 2016 | 314 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2019 | 441 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 741 | 0.030 |
Why?
| | Quality of Life | 2 | 2024 | 3210 | 0.030 |
Why?
| | Washington | 1 | 2015 | 149 | 0.030 |
Why?
| | Solubility | 1 | 2015 | 240 | 0.030 |
Why?
| | Area Under Curve | 1 | 2015 | 332 | 0.030 |
Why?
| | Airway Management | 1 | 2015 | 81 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 699 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2015 | 387 | 0.030 |
Why?
| | Insulin, Long-Acting | 2 | 2005 | 65 | 0.030 |
Why?
| | Blood Pressure Determination | 1 | 2015 | 145 | 0.030 |
Why?
| | Tunica Intima | 3 | 2000 | 78 | 0.030 |
Why?
| | Insulin Glargine | 2 | 2005 | 88 | 0.030 |
Why?
| | Achievement | 1 | 2014 | 58 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2015 | 150 | 0.030 |
Why?
| | Epidemiologic Factors | 1 | 2013 | 10 | 0.030 |
Why?
| | Family Characteristics | 1 | 2015 | 197 | 0.020 |
Why?
| | Antigen-Antibody Reactions | 1 | 2013 | 49 | 0.020 |
Why?
| | Asthma | 1 | 2025 | 1797 | 0.020 |
Why?
| | Hospitalization | 1 | 2004 | 2460 | 0.020 |
Why?
| | Plaque, Atherosclerotic | 1 | 2014 | 61 | 0.020 |
Why?
| | Base Sequence | 2 | 2011 | 2171 | 0.020 |
Why?
| | Complement C1 Inactivator Proteins | 1 | 2012 | 6 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2015 | 310 | 0.020 |
Why?
| | Nurses | 1 | 2015 | 171 | 0.020 |
Why?
| | Complement C1 Inhibitor Protein | 1 | 2012 | 12 | 0.020 |
Why?
| | S100 Calcium Binding Protein beta Subunit | 1 | 2012 | 9 | 0.020 |
Why?
| | Albumins | 1 | 2013 | 119 | 0.020 |
Why?
| | S100 Proteins | 1 | 2012 | 35 | 0.020 |
Why?
| | Vaccines, Inactivated | 1 | 2012 | 70 | 0.020 |
Why?
| | Biometry | 1 | 1993 | 66 | 0.020 |
Why?
| | California | 2 | 2004 | 473 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1662 | 0.020 |
Why?
| | Niacinamide | 1 | 1993 | 104 | 0.020 |
Why?
| | Luciferases | 1 | 2012 | 154 | 0.020 |
Why?
| | Intubation, Intratracheal | 1 | 2015 | 327 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2012 | 149 | 0.020 |
Why?
| | Genome | 1 | 2014 | 305 | 0.020 |
Why?
| | Aging | 3 | 2000 | 1973 | 0.020 |
Why?
| | Nerve Growth Factors | 1 | 2012 | 79 | 0.020 |
Why?
| | Nitrates | 1 | 1992 | 96 | 0.020 |
Why?
| | Phylogeny | 2 | 2006 | 917 | 0.020 |
Why?
| | Water Supply | 1 | 1992 | 89 | 0.020 |
Why?
| | Diagnostic Techniques, Endocrine | 1 | 2011 | 15 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 1998 | 923 | 0.020 |
Why?
| | Observation | 1 | 2011 | 54 | 0.020 |
Why?
| | 25-Hydroxyvitamin D 2 | 1 | 2011 | 6 | 0.020 |
Why?
| | Potassium Channels | 1 | 2012 | 148 | 0.020 |
Why?
| | Adenosine Triphosphatases | 1 | 2012 | 159 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2014 | 375 | 0.020 |
Why?
| | Ubiquitins | 1 | 2011 | 31 | 0.020 |
Why?
| | Abdominal Fat | 1 | 2012 | 51 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2011 | 1512 | 0.020 |
Why?
| | Insulinoma | 1 | 2011 | 29 | 0.020 |
Why?
| | Iodine Radioisotopes | 1 | 2011 | 138 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 331 | 0.020 |
Why?
| | Dietary Fats, Unsaturated | 1 | 2011 | 24 | 0.020 |
Why?
| | Causality | 1 | 1991 | 127 | 0.020 |
Why?
| | Societies, Medical | 1 | 2015 | 900 | 0.020 |
Why?
| | Peptide Fragments | 2 | 2007 | 696 | 0.020 |
Why?
| | Leptin | 1 | 2012 | 248 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2015 | 587 | 0.020 |
Why?
| | Brain | 1 | 2023 | 2969 | 0.020 |
Why?
| | Endothelium, Vascular | 2 | 2008 | 956 | 0.020 |
Why?
| | Radioimmunoprecipitation Assay | 1 | 2009 | 6 | 0.020 |
Why?
| | Microchemistry | 1 | 2009 | 19 | 0.020 |
Why?
| | Staphylococcal Protein A | 1 | 2009 | 12 | 0.020 |
Why?
| | Biostatistics | 1 | 2009 | 19 | 0.020 |
Why?
| | Cholera Toxin | 1 | 2009 | 29 | 0.020 |
Why?
| | Fetal Weight | 1 | 2009 | 53 | 0.020 |
Why?
| | Graves Disease | 1 | 2009 | 32 | 0.020 |
Why?
| | DNA Replication | 1 | 2011 | 249 | 0.020 |
Why?
| | Calibration | 1 | 2009 | 152 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 410 | 0.020 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 101 | 0.020 |
Why?
| | Pancreatic Polypeptide | 1 | 1989 | 4 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2018 | 8346 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 528 | 0.020 |
Why?
| | Intestinal Absorption | 1 | 2009 | 103 | 0.020 |
Why?
| | Vaccination | 1 | 2017 | 1428 | 0.020 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2008 | 28 | 0.020 |
Why?
| | Radiography | 1 | 2011 | 853 | 0.020 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2008 | 43 | 0.020 |
Why?
| | Interferon-Induced Helicase, IFIH1 | 1 | 2008 | 19 | 0.020 |
Why?
| | Tunica Media | 2 | 2000 | 37 | 0.020 |
Why?
| | Protein Precursors | 1 | 2009 | 136 | 0.020 |
Why?
| | Survival Rate | 2 | 2006 | 2094 | 0.020 |
Why?
| | Personality Inventory | 1 | 2009 | 134 | 0.020 |
Why?
| | Interferon-alpha | 1 | 2009 | 193 | 0.020 |
Why?
| | Telecommunications | 1 | 1988 | 19 | 0.020 |
Why?
| | Genetic Carrier Screening | 1 | 2008 | 32 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2000 | 979 | 0.020 |
Why?
| | Nutrition Therapy | 1 | 2008 | 37 | 0.020 |
Why?
| | Pacific Islands | 1 | 1988 | 5 | 0.020 |
Why?
| | Solanum tuberosum | 1 | 2008 | 8 | 0.020 |
Why?
| | Probability | 1 | 1989 | 308 | 0.020 |
Why?
| | Americas | 1 | 1988 | 27 | 0.020 |
Why?
| | Outpatients | 1 | 1992 | 447 | 0.020 |
Why?
| | Asia | 1 | 1988 | 70 | 0.020 |
Why?
| | Glucagon | 1 | 1989 | 114 | 0.020 |
Why?
| | Diabetic Neuropathies | 1 | 2009 | 100 | 0.020 |
Why?
| | Pregnancy in Diabetics | 1 | 2009 | 123 | 0.020 |
Why?
| | Survival | 1 | 2007 | 38 | 0.020 |
Why?
| | Bottle Feeding | 1 | 2007 | 19 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2008 | 175 | 0.020 |
Why?
| | Vegetables | 1 | 2008 | 162 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2011 | 1723 | 0.020 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2006 | 47 | 0.020 |
Why?
| | 5' Untranslated Regions | 1 | 2006 | 59 | 0.020 |
Why?
| | Molecular Epidemiology | 1 | 2006 | 74 | 0.010 |
Why?
| | Protein Array Analysis | 1 | 2006 | 56 | 0.010 |
Why?
| | DNA-Directed RNA Polymerases | 1 | 2006 | 62 | 0.010 |
Why?
| | Serotyping | 1 | 2005 | 31 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2013 | 1505 | 0.010 |
Why?
| | Sequence Alignment | 1 | 2006 | 362 | 0.010 |
Why?
| | Self Care | 1 | 2009 | 392 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2013 | 2805 | 0.010 |
Why?
| | Species Specificity | 1 | 2006 | 546 | 0.010 |
Why?
| | Alprostadil | 1 | 2005 | 29 | 0.010 |
Why?
| | Cause of Death | 2 | 2002 | 471 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2006 | 368 | 0.010 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2005 | 148 | 0.010 |
Why?
| | Polyethylene Glycols | 1 | 2009 | 649 | 0.010 |
Why?
| | Puerto Rico | 1 | 2004 | 63 | 0.010 |
Why?
| | Dinoprostone | 1 | 2005 | 180 | 0.010 |
Why?
| | Ultrasonography | 2 | 2000 | 788 | 0.010 |
Why?
| | False Positive Reactions | 1 | 2004 | 123 | 0.010 |
Why?
| | Treatment Outcome | 2 | 2004 | 11793 | 0.010 |
Why?
| | Genome, Viral | 1 | 2005 | 214 | 0.010 |
Why?
| | Embryonic and Fetal Development | 1 | 2003 | 93 | 0.010 |
Why?
| | Regeneration | 1 | 2005 | 198 | 0.010 |
Why?
| | Mutation | 1 | 2015 | 4090 | 0.010 |
Why?
| | Insulin Lispro | 1 | 2003 | 42 | 0.010 |
Why?
| | DNA, Viral | 1 | 2005 | 356 | 0.010 |
Why?
| | Single-Blind Method | 1 | 2004 | 318 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2008 | 2191 | 0.010 |
Why?
| | Guidelines as Topic | 1 | 2005 | 268 | 0.010 |
Why?
| | Health | 1 | 2003 | 82 | 0.010 |
Why?
| | Duodenum | 1 | 2003 | 77 | 0.010 |
Why?
| | Income | 1 | 2003 | 203 | 0.010 |
Why?
| | HLA-A Antigens | 1 | 2002 | 52 | 0.010 |
Why?
| | Models, Immunological | 1 | 2002 | 99 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2008 | 4151 | 0.010 |
Why?
| | Mental Recall | 1 | 2003 | 223 | 0.010 |
Why?
| | Blotting, Southern | 1 | 2000 | 85 | 0.010 |
Why?
| | Carotid Artery, Internal | 1 | 2000 | 45 | 0.010 |
Why?
| | Carotid Artery, Common | 1 | 2000 | 31 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2000 | 273 | 0.010 |
Why?
| | Circadian Rhythm | 1 | 1985 | 513 | 0.010 |
Why?
| | Cholesterol, VLDL | 1 | 1999 | 5 | 0.010 |
Why?
| | Acute Disease | 1 | 2002 | 1036 | 0.010 |
Why?
| | Genetic Counseling | 1 | 1999 | 80 | 0.010 |
Why?
| | Twins, Dizygotic | 1 | 1999 | 108 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 5223 | 0.010 |
Why?
| | Twins, Monozygotic | 1 | 1999 | 133 | 0.010 |
Why?
| | Lymphocyte Count | 1 | 1998 | 165 | 0.010 |
Why?
| | CD4 Lymphocyte Count | 1 | 1998 | 280 | 0.010 |
Why?
| | Demography | 1 | 1998 | 282 | 0.010 |
Why?
| | Arthritis, Rheumatoid | 1 | 2006 | 1180 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2006 | 2601 | 0.010 |
Why?
| | Quantitative Trait, Heritable | 1 | 1997 | 114 | 0.010 |
Why?
| | Cholesterol, LDL | 1 | 1998 | 360 | 0.010 |
Why?
| | Bacterial Infections | 1 | 1998 | 246 | 0.010 |
Why?
| | T-Lymphocyte Subsets | 1 | 1998 | 420 | 0.010 |
Why?
| | Mexico | 1 | 1996 | 233 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2000 | 2525 | 0.010 |
Why?
| | Mental Disorders | 1 | 2002 | 1169 | 0.010 |
Why?
| | Baltic States | 1 | 1992 | 1 | 0.010 |
Why?
| | Rats | 1 | 2000 | 5585 | 0.010 |
Why?
| | Energy Metabolism | 1 | 1998 | 935 | 0.010 |
Why?
| | Geography | 1 | 1992 | 187 | 0.010 |
Why?
| | Software | 1 | 1997 | 680 | 0.010 |
Why?
| | Cohort Effect | 1 | 1990 | 4 | 0.000 |
Why?
| | Periodicity | 1 | 1990 | 58 | 0.000 |
Why?
| | Space-Time Clustering | 1 | 1989 | 3 | 0.000 |
Why?
| | Actuarial Analysis | 1 | 1989 | 16 | 0.000 |
Why?
| | Coxsackievirus Infections | 1 | 1987 | 14 | 0.000 |
Why?
| | Rubella | 1 | 1987 | 23 | 0.000 |
Why?
| | Mortality | 1 | 1989 | 380 | 0.000 |
Why?
| | Neoplasms | 1 | 1989 | 2913 | 0.000 |
Why?
|
|
Rewers's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|